Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
CAPR
$27.91
$
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.
Next Earnings
2026-02-25
Beta
0.402
Average Volume
Market Cap
Last Dividend
CIK
0001133869
ISIN
US14070B3096
CUSIP
14070B309
CEO
Linda Marbán
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
160
IPO Date
2007-02-13
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| GSA Capital Partners LLP Makes New $1.56 Million Investment in Capricor Therapeutics, Inc. $CAPR | GSA Capital Partners LLP purchased a new stake in Capricor Therapeutics, Inc. (NASDAQ: CAPR) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 215,675 shares of the biotechnology company's stock, valued at approximately $1,555,000. GSA Capital Partners LLP owned about | Defense World | 2026-02-18 04:16:56 |
| CAPR Updates FDA on Deramiocel BLA, Plans HOPE-3 CSR Filing in February | CAPR said the FDA wants the full HOPE-3 study report for Deramiocel and confirmed no new clinical trials are needed. | Zacks Investment Research | 2026-01-21 11:50:54 |
| Maravai LifeSciences (NASDAQ:MRVI) & Capricor Therapeutics (NASDAQ:CAPR) Critical Review | Capricor Therapeutics (NASDAQ: CAPR - Get Free Report) and Maravai LifeSciences (NASDAQ: MRVI - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk. Profitability This table compares Capricor Therapeutics and | Defense World | 2026-01-12 01:10:52 |
| Here's Why This Biotechnology Skyrocketed by 439% in December | The Phase 3 trial met its primary and secondary endpoints. Management anticipates approval in 2026, with highly lucrative milestone payments expected to follow in the years to come. | The Motley Fool | 2026-01-09 05:41:00 |
| Capricor Therapeutics (NASDAQ:CAPR) versus Glucose Health (OTCMKTS:GLUC) Head to Head Survey | Capricor Therapeutics (NASDAQ: CAPR - Get Free Report) and Glucose Health (OTCMKTS:GLUC - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, analyst recommendations, risk, dividends and valuation. Profitability This table compares Capricor Therapeutics and | Defense World | 2025-12-31 01:26:53 |
| Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Trial Results and Regulatory Path for Duchenne Muscular Dystrophy Therapy Transcript | Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Trial Results and Regulatory Path for Duchenne Muscular Dystrophy Therapy Transcript | Seeking Alpha | 2025-12-17 19:59:03 |
| Caprock Provides Update on Drilling and Announces Expansion of Drill Program at Its Destiny Gold Project | Toronto, Ontario--(Newsfile Corp. - December 17, 2025) - Caprock Mining Corp. (CSE: CAPR) ("Caprock" or the "Company") is pleased to provide an | Newsfile Corp | 2025-12-17 08:00:00 |
| Caprock Announces Closing of Private Placement and Confirmation of Payment of Anniversary Payment on Destiny Option | Toronto, Ontario--(Newsfile Corp. - December 12, 2025) - Caprock Mining Corp. (CSE: CAPR) ("Caprock" or the "Company") is pleased to announce that | Newsfile Corp | 2025-12-12 16:15:00 |
| Martin Shkreli's Biotech Short Position Is Blowing Up As Stock Soars 440%: Momentum Score Spikes | Investor Martin Shkreli's big biotech short position is blowing up after the stock's monumental rally over the past week. | Benzinga | 2025-12-08 04:31:39 |
| Capricor: Maintaining 'Hold' Rating On Randomized Phase 3 HOPE-3 Trial Win With Deramiocel | Capricor Therapeutics maintains a "Hold" rating despite positive phase 3 HOPE-3 results for Deramiocel in DMD cardiomyopathy. HOPE-3 met both primary [PUL v2.0] and key secondary [LVEF] endpoints, aligning with FDA's requirements for potential BLA resubmission of Deramiocel. Regulatory uncertainty remains, particularly regarding CMC issues and whether or not HOPE-3 fully satisfies FDA approval criteria. | Seeking Alpha | 2025-12-07 08:21:00 |
| Biotech Stocks To Add to Your Watchlist – December 5th | Danaher, Moderna, and Capricor Therapeutics are the three Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of companies that develop medicines, biologics, diagnostics, or other technologies based on biological science and genetic research. For investors, they tend to be high-risk, high-reward assets whose value is driven by clinical | Defense World | 2025-12-07 02:04:54 |
| Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Top Line Data for Deramiocel in Duchenne Muscular Dystrophy Transcript | Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Top Line Data for Deramiocel in Duchenne Muscular Dystrophy Transcript | Seeking Alpha | 2025-12-06 01:18:57 |
| CAPR Stock Skyrockets 282% in a Week: Here's What You Need to Know | Capricor Therapeutics stock soars after meeting key goals with statistical significance in a phase III study of deramiocel for Duchenne cardiomyopathy. | Zacks Investment Research | 2025-12-05 11:36:04 |
| Caprock Announces Proposed Private Placement | Toronto, Ontario--(Newsfile Corp. - December 4, 2025) - Caprock Mining Corp. (CSE: CAPR) ("Caprock" or the "Company") is pleased to | Newsfile Corp | 2025-12-04 16:15:00 |
| Capricor Therapeutics Announces Proposed Public Offering of Common Stock | SAN DIEGO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics, today announced the commencement of a proposed underwritten public offering of shares of its common stock. In addition, Capricor intends to grant the underwriters a 30-day option to purchase an additional number of shares of common stock equal to 15% of the aggregate number of shares of its common stock sold in the public offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. | GlobeNewsWire | 2025-12-04 16:01:00 |
| Martin Shkreli touts QCLS stock as a long idea after a “bad call” on CAPR | Q/C Technologies In (NASDAQ: QCLS) soared another 60% on Thursday morning after former pharmaceutical executive Martin Shkreli touted the company as a “long idea”. According to him, the photonic computing firm could be trading at $100 per share, and that too in the near-term. | Invezz | 2025-12-04 12:05:50 |
| Capricor Stock Soars, Shkreli Is Short: Here's What Pharma Bro Had To Say | Capricor Therapeutics, Inc. (NASDAQ: CAPR) stock soared on Wednesday after the company announced positive topline data from the Phase 3 HOPE-3 trial for its lead cell therapy candidate, deramiocel. | Benzinga | 2025-12-03 14:21:55 |
| Biotech Stock Up Over 400% After Late-Stage Breakthrough | Capricor Therapeutics Inc (NASDAQ:CAPR) is one of the best stocks on Wall Street today, up 263% to trade at $23.09, after the biotech company's cell therapy for a heart condition related to Duchenne's muscular dystrophy met the main goal of a late-stage study. | Schaeffers Research | 2025-12-03 10:36:41 |
| Capricor Therapeutics Duchenne Treatment Shows Strong Heart And Muscle Results In Trial | Capricor Therapeutics Inc. (NASDAQ: CAPR) stock is rallying on Wednesday. | Benzinga | 2025-12-03 09:23:14 |
| Capricor's muscle disorder cell therapy succeeds in late-stage study | Capricor Therapeutics said on Wednesday its cell therapy for a heart condition related to a rare muscular disorder met the main goal of a late-stage study, months after U.S. regulators rejected its initial approval bid. | Reuters | 2025-12-03 07:44:39 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| SC 13G/A | 2026-02-17 | 2026-02-17 | View Filing |
| S-8 | 2026-01-30 | 2026-01-30 | View Filing |
| SC 13G | 2026-01-26 | 2026-01-26 | View Filing |
| 4 | 2026-01-07 | 2026-01-07 | View Filing |
| 4 | 2026-01-07 | 2026-01-07 | View Filing |
| 4 | 2026-01-07 | 2026-01-07 | View Filing |
| 4 | 2026-01-07 | 2026-01-07 | View Filing |
| 4 | 2026-01-07 | 2026-01-07 | View Filing |
| 4 | 2026-01-07 | 2026-01-07 | View Filing |
| 4 | 2026-01-07 | 2026-01-07 | View Filing |
| 4 | 2026-01-07 | 2026-01-07 | View Filing |
| 4 | 2026-01-07 | 2026-01-07 | View Filing |
| 4 | 2026-01-07 | 2026-01-07 | View Filing |
| 4 | 2025-12-23 | 2025-12-23 | View Filing |
| 424B5 | 2025-12-05 | 2025-12-05 | View Filing |
| 8-K | 2025-12-05 | 2025-12-05 | View Filing |
| 424B3 | 2025-12-05 | 2025-12-05 | View Filing |
| 424B5 | 2025-12-04 | 2025-12-04 | View Filing |
| 8-K | 2025-12-03 | 2025-12-03 | View Filing |
| 8-K | 2025-12-03 | 2025-12-03 | View Filing |
| 10-Q | 2025-11-10 | 2025-11-10 | View Filing |
| 8-K | 2025-11-10 | 2025-11-10 | View Filing |
| SC 13G/A | 2025-10-30 | 2025-10-30 | View Filing |
| EFFECT | 2025-09-24 | 2025-09-24 | View Filing |
| S-3 | 2025-09-10 | 2025-09-10 | View Filing |
| 10-Q | 2025-08-11 | 2025-08-11 | View Filing |
| 8-K | 2025-08-11 | 2025-08-11 | View Filing |
| SC 13G | 2025-07-29 | 2025-07-29 | View Filing |
| 8-K | 2025-07-11 | 2025-07-11 | View Filing |
| S-8 | 2025-06-16 | 2025-06-16 | View Filing |
| 8-K | 2025-05-27 | 2025-05-27 | View Filing |
| 10-Q | 2025-05-14 | 2025-05-14 | View Filing |
| 8-K | 2025-05-13 | 2025-05-13 | View Filing |
| SC 13G/A | 2025-04-30 | 2025-04-30 | View Filing |
| ARS | 2025-04-09 | 2025-04-09 | View Filing |
| DEF 14A | 2025-04-08 | 2025-04-08 | View Filing |
| 8-K | 2025-04-08 | 2025-04-08 | View Filing |
| 10-K | 2025-03-26 | 2025-03-26 | View Filing |
| 8-K | 2025-03-19 | 2025-03-19 | View Filing |
| 4 | 2025-03-05 | 2025-03-05 | View Filing |
| 4 | 2025-03-04 | 2025-03-04 | View Filing |
| 4 | 2025-03-04 | 2025-03-04 | View Filing |
| 4 | 2025-03-04 | 2025-03-04 | View Filing |
| 8-K | 2025-03-04 | 2025-03-04 | View Filing |
| 4 | 2025-02-28 | 2025-02-28 | View Filing |
| SC 13G/A | 2025-02-05 | 2025-02-05 | View Filing |
| S-8 | 2025-02-05 | 2025-02-05 | View Filing |
| SC 13G | 2025-01-30 | 2025-01-30 | View Filing |
| 4 | 2025-01-06 | 2025-01-06 | View Filing |
| 4 | 2025-01-06 | 2025-01-06 | View Filing |
| 4 | 2025-01-06 | 2025-01-06 | View Filing |
| 4 | 2025-01-06 | 2025-01-06 | View Filing |
| 4 | 2025-01-06 | 2025-01-06 | View Filing |
| 4 | 2025-01-06 | 2025-01-06 | View Filing |
| 4 | 2025-01-06 | 2025-01-06 | View Filing |
| 4 | 2025-01-06 | 2025-01-06 | View Filing |
| 4 | 2025-01-06 | 2025-01-06 | View Filing |
| 4 | 2025-01-06 | 2025-01-06 | View Filing |
| 4 | 2025-01-06 | 2025-01-06 | View Filing |
| 8-K | 2025-01-02 | 2025-01-02 | View Filing |
| 4 | 2024-12-16 | 2024-12-16 | View Filing |
| 4 | 2024-12-04 | 2024-12-04 | View Filing |
| 10-Q | 2024-11-14 | 2024-11-14 | View Filing |
| 8-K | 2024-11-13 | 2024-11-13 | View Filing |
| SC 13G | 2024-11-12 | 2024-11-12 | View Filing |
| EFFECT | 2024-11-12 | 2024-11-12 | View Filing |
| SC 13G/A | 2024-11-08 | 2024-11-08 | View Filing |
| SC 13G | 2024-10-24 | 2024-10-24 | View Filing |
| S-3 | 2024-10-22 | 2024-10-22 | View Filing |
| 424B5 | 2024-10-17 | 2024-10-17 | View Filing |
| 8-K | 2024-10-17 | 2024-10-17 | View Filing |
| EFFECT | 2024-10-17 | 2024-10-17 | View Filing |
| 424B5 | 2024-10-16 | 2024-10-16 | View Filing |
| 8-K | 2024-10-16 | 2024-10-16 | View Filing |
| S-3/A | 2024-10-16 | 2024-10-16 | View Filing |
| 8-K | 2024-10-09 | 2024-10-09 | View Filing |
| SC 13G/A | 2024-09-24 | 2024-09-24 | View Filing |
| 8-K | 2024-09-24 | 2024-09-24 | View Filing |
| 4 | 2024-09-24 | 2024-09-24 | View Filing |
| 8-K | 2024-09-17 | 2024-09-17 | View Filing |
| 3 | 2024-08-23 | 2024-08-23 | View Filing |
| SC 13G/A | 2024-08-23 | 2024-08-23 | View Filing |
| 4 | 2024-08-09 | 2024-08-09 | View Filing |
| 10-Q | 2024-08-08 | 2024-08-08 | View Filing |
| 8-K | 2024-08-07 | 2024-08-07 | View Filing |
| S-3 | 2024-06-14 | 2024-06-14 | View Filing |
| 8-K | 2024-05-15 | 2024-05-15 | View Filing |
| 8-K | 2024-05-15 | 2024-05-15 | View Filing |
| 10-Q | 2024-05-14 | 2024-05-14 | View Filing |
| 8-K | 2024-05-13 | 2024-05-13 | View Filing |
| 8-K | 2024-04-29 | 2024-04-29 | View Filing |
| 4 | 2024-04-25 | 2024-04-25 | View Filing |
| 4 | 2024-04-24 | 2024-04-24 | View Filing |
| ARS | 2024-04-01 | 2024-04-01 | View Filing |
| DEF 14A | 2024-04-01 | 2024-03-29 | View Filing |
| PRE 14A | 2024-03-20 | 2024-03-20 | View Filing |
| 10-K | 2024-03-11 | 2024-03-11 | View Filing |
| 8-K | 2024-02-29 | 2024-02-29 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Quantum Inspired Strategy | 690.85% | 0.99 | 528 | 0.02 | 0.54 | 436.42 |
| Super Trend Strategy | 635.22% | 0.99 | 1045 | 0.02 | 0.42 | 380.79 |
| Bull Bias | 559.68% | 0.99 | 1045 | 0.02 | 0.47 | 305.25 |
| xxxxxxxxxxxxxx | xxxxxx% | x | xxxx | xxxx | xxx | xxxxxx |
| xxxxxxxxx | xxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxxx |
| xxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xxx | xxxx | xxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xxxx | xxxx | xxxx | xxxxx |
| xxxxxxxxx | xxxxxx% | xxxx | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xxxx | xxxx | xxx | x |
| xxxxxxxxxxxxx | xxxxxx% | xxxx | xxxx | xxxx | xxx | x |
| xxxxxxxxxx | xxxxxx% | xxxx | xxxx | xxxx | xxx | xxxxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxx | xxxxx% | xxxx | xx | xxxx | xxxx | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxxx |
| xxxxxxxxxx | xxxxxxx% | x | xxxx | xxxx | xxxx | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | xxxx | xxx | xxxx | xxxx | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxxx |
| xxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxxx |
| xxxx | xxxxx% | x | xxxx | xxxx | xxxx | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | x | xxxx | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xxx | x | xxxx | xxxxxx |
| xxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | x | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxxx |
| xxxxxxxxxxxx | xxxxxxxx% | x | xxx | x | x | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxxx |
| xxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxxx |
| xxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxxx | xxxxx | xxxxx | xxxxxx |